Literature DB >> 8356250

The need for aggressive therapy of rheumatoid arthritis.

K R Wilske1, L A Healey.   

Abstract

We are on the threshold of a new era in the treatment of RA if we learn from the experience of the past and utilize new techniques and therapeutic modalities that the future will bring. New strategies and treatment of RA in the future will need to include earlier recognition of progressive disease, earlier interventions, new preparations for use in therapeutic armamentarium, combinations of agents, and monitoring of long-term outcomes to assess results over 5 to 10 years. There is always concern about new therapies and strategies. As noted by Huskisson, however, "In the absence of knowledge about the cause of disease and the mode of action of the drugs, the only way forward is by clinical trials of different preparations. With trial, there is always the risk of error." Our greatest error, however, will be if we ignore lessons from the past, fail to control the inflammatory process early, and continue to spend years writing "doing well" in the charts of patients who become progressively disabled before our eyes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8356250

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  4 in total

Review 1.  [Cortisone therapy today].

Authors:  Hanns Kaiser
Journal:  Wien Klin Wochenschr       Date:  2003-01-31       Impact factor: 1.704

2.  Esophageal motility disorder in a patient with rheumatoid arthritis.

Authors:  K Ozoran; B Sivri; S Ataman; S Unai
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

3.  Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study.

Authors:  D Aletaha; T Stamm; T Kapral; G Eberl; J Grisar; K P Machold; J S Smolen
Journal:  Ann Rheum Dis       Date:  2003-10       Impact factor: 19.103

4.  Survival analysis of disease modifying antirheumatic drugs in Spanish rheumatoid arthritis patients.

Authors:  J De La Mata; F J Blanco; J J Gómez-Reino
Journal:  Ann Rheum Dis       Date:  1995-11       Impact factor: 19.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.